Angiodynamics (ANGO) Asset Writedowns and Impairment (2010 - 2026)

Angiodynamics (ANGO) has 17 years of Asset Writedowns and Impairment data on file, last reported at $986000.0 in Q2 2026.

• Quarterly Asset Writedowns and Impairment rose 1116.49% year-over-year to $986000.0 in Q2 2026, while the trailing twelve-month figure through May 2026 was $1.3 million (changed N/A YoY) and the FY2026 annual result came in at $1.3 million, changed N/A from the prior year.
• Asset Writedowns and Impairment improved to $986000.0 in Q2 2026, from $38000.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $3.4 million in Q1 2024 to a low of -$158.6 million in Q2 2024.
• A 5-year average of -$9.0 million and a median of $38000.0 in 2025 frame the typical range for Asset Writedowns and Impairment.
• The widest YoY moves for Asset Writedowns and Impairment: up 5864.91% in 2024, down 110043.75% in 2024.
• Tracing ANGO's Asset Writedowns and Impairment over 5 years: stood at $87000.0 in 2022, then slumped by 824.14% to -$630000.0 in 2023, then soared by 66.51% to -$211000.0 in 2024, then surged by 245.5% to $307000.0 in 2025, then jumped by 221.17% to $986000.0 in 2026.
• The last three Asset Writedowns and Impairment figures came in at $986000.0 (Q2 2026), $38000.0 (Q1 2026), and $307000.0 (Q4 2025), per Business Quant data.